UNIVERSITY OF SASSARI PERSONAL INFORMATION Surname and Name: Bagella Luigi Marco • Orcid identifier: 0000-0003-2815-037X • E-mail: [email protected] [email protected] EDUCATIONAL BACKGROUND • Pharm. Degree, Summa cum Laude, University of Sassari (Italy) • Ph.D. in "Diagnostic and Quantitative Pathology" Institute of Pathological Anatomy, University of Siena (Italy) CURRENT POSITIONS • 2006-present, Associate Professor of Medical Chemistry and Biochemistry, Scientific-Disciplinary Sector BIO/10, Department of Biomedical Science, University of Sassari (Italy) • 2007-present, Adjunct Associate Professor, Sbarro Institute for Cancer Research and Molecular Medicine, Department of Biology, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA (USA) HONORS/AWARDS AND SCOLARSHIPS • 1995-1996, Recipient of AIRC/FIRC fellowship for abroad - Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia, PA USA • 2009, Recipient of “Premialità Regionale 2009” from R.A.S: Regione Autonoma della Sardegna. • 2012, Recipient of “Scientific Productivity 2012” during the celebration of the 450th anniversary of the establishment of the University of Sassari (Italy), March 24, 2012 TEACHING ACTIVITIES • 2006–present, Course in Chemistry and Propedeutical Biochemistry (5 credits), School of Medicine and Surgery, University of Sassari (Italy) • 2006–present, Course in Chemistry and Propedeutical Biochemistry (6 credits), School of Dentistry, University of Sassari (Italy). • 2010–present, Course in Molecular Models and Oncological Pathologies (5 credits) (Molecular Medicine), School of Sanitary, Medical and Veterinary Biotechnology, University of Sassari (Italy). • 2014–present, Course in Biochemistry (9 credits), School of Medicine and Surgery, University of Sassari (Italy). UNIVERSITY OF SASSARI UNIVERSITY OF SASSARI MEMBERSHIPS OF INTERUNIVERSITY CONSORTIUMS AND SCIENTIFIC SOCIETIES • I.N.B.B. - Biostructures and Biosystems National Institute • SIB - Italian Society of Biochemistry and Molecular Biology OVERVIEW OF THE SCIENTIFIC ACTIVITY AND OUTPUT Research activity is focused to clarify the molecular mechanisms controlling cell cycle and differentiation. Responsible for nationally and internationally funded programmes, which focus in the study of genes involved in cell cycle regulation and differentiation through the analysis of molecular pathways in experimental models: 1.Characterization of the cyclin-dependent kinases: Cdk10 and its regulatory subunits. 2.Role of the complex CDK9 / CiclinaT2 in skeletal muscle differentiation. 3.The role of EZH2 in the process of carcinogenesis in rhabdomyosarcoma. 4. Study on the prevention/early detection of lung cancer performed on patients with smoking-related respiratory diseases. 5.Analysis of gene expression and cytometric in patients with Chronic Obstructive Pulmonary order to identify new predictors of lung cancer. 6.Molecular mechanisms responsible for the neoplastic transformation with particular reference to the identification of specific targets for the development of new therapeutic strategies 7.Analysis of the cytotoxic activity of new small molecules with antiproliferative activity National and international scientific collaborations: a.Role of viral infection during the tumor progression. – Prof. Antonio Giordano, Director of the Sbarro Institute for Cancer Research and Molecular Medicine, College of Science & Technology, Temple University Philadelphia, USA b.Synthesis and antiproliferative activity of novel unsymmetrical 1,3,4-Oxadiazole against select cancer cell lines. – Prof. Gerard Aime Pinna, Department of Chemistry and Pharmacy, University of Sassari. c. Role of different factors remodelling chromatin in stem cells. - Prof. Umberto Galderisi, Department of Experimental Medicine, Second University of Naples. d.Identification of "small molecules" based on the amino acid sequence of the tumor suppressor p130/pRb2 gene: Characterization of "Spa310" and derivatives, as prospective candidates for cancer therapy. – Prof. Antonio Giordano, Director of the Sbarro Institute for Cancer Research and Molecular Medicine, College of Science & Technology, Temple University Philadelphia, USA e. Role of DNA Repair in Genomic and Epigenomic Stability. – Prof. Alfonso Bellacosa, Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, USA f. Role of the promyelocytic leukemia protein (PML) on angiogenesis in human neuroblastoma. – Prof. Arturo Sala, Brunel Institute for Cancer Genetics and Pharmacogenomics, London. g.Terminal differentiation reprogramming of rhabdomyosarcoma: a potential therapeutic approach targeting polycomb–SWI/SNF. – Prof. Sonia-Vanina Forcales Fernandez, Institute for Predictive and Personalized Medicine of Cancer (IMPPC), Barcelona. h.Efflux pump inhibitors: synthesis and evaluation of innovative molecular tools in order to tackle drug resistance in cancer therapy. – Prof. Antonello Carta, Department of Chemistry and Pharmacy, University of Sassari. UNIVERSITY OF SASSARI UNIVERSITY OF SASSARI SCIENTIFIC PUBLICATIONS • 63 publications in extensor: • 49 in international journal widely recognized by the scientific community and classified by the Institute for Scientific Information (ISI) of Philadelphia • 06 in books and journals not indexed • 08 in contributions in conference proceedings For the publications in international journals: • Average Impact Factor: 6,17 • Hirsch Index: 27 • Sum of total citations: 2773 • Average citations per year of professional activity: 120.56 SELECTED PUBLICATIONS 1 Sanna L., Marchesi I., Melone M.A.B., Bagella L. The role of enhancer of zeste homolog 2: From viral epigenetics to the carcinogenesis of hepatocellular carcinoma. J. Cell. Physiol. 233(9): 6508-6517 (2018). 2 Marchesi I., Sanna L., Fais M., Fiorentino F.P., Giordano A., Bagella L. D12-O-tetradecanoylphorbol-13-acetate and EZH2 inhibition: A novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells. J Cell Physiol. 233(3): 2360-2365 (2018). 3 Nieddu V., Pinna G., Marchesi I., Sanna L., Asproni B., Pinna G.A., Bagella L., Murineddu G. Synthesis and Antineoplastic Evaluation of Novel Unsymmetrical 1,3,4-Oxadiazoles. Journal Of Medicinal Chemistry 59(23): 10451-10469 (2016). 4 Dvorkina M., Nieddu V., Chakelam S., Pezzolo A., Cantilena S., LeiteA.P., Chayka O., Regad T., Pistorio A., Sementa A.R., Lechertier T., Morgenstern D., Lebras M., Burns A., Saunders N., Anderson J., Hodivala-Dilke K., Bagella L., De The H., Sebire N., Pistoia V., Sala A. and Salomoni P. Promyelocytic leukaemia protein (pml) is an angiogenesis inhibitor and relapse biomarker in neuroblastoma. Clinical Cancer Research 22(13): 3398-409 (2016). 5 Marchesi I, Giordano A, Bagella L. Roles of enhancer of zeste homolog 2: From skeletal muscle differentiation to rhadbomyosarcoma carcinogenesis. Cell Cycle 13(4): 516-527 (2014). 6 D’Urso V, Doneddu V, Marchesi I, Collodoro A, Pirina P, Giordano A, Bagella L. Sputum analysis: non-invasive early lung cancer detection. J Cell Physiol. 228(5): 945-51 (2013). 7 Marchesi I., Fiorentino F.P., Rizzolio F., Giordano A., Bagella L. The ablation of Ezh2 uncovers its crucial role in the rhabdomyosarcoma formation. Cell Cycle 11(20): 3828-36 (2012). 8 Rizzolio F., Lucchetti C., Caligiuri I., Marchesi I., Caputo M., Klein-Szanto A.J., Bagella L., Castronovo M., Giordano A. Retinoblastoma tumor-suppressor protein phosphorylation and inactivation depend on direct interaction with Pin1. Cell Death Differ. 19(7): 1152-61 (2012). 9 Fiorentino F.P., Macaluso M., Miranda F., Montanari M., Russo A., Bagella L., Giordano A. CTCF and BORIS Regulate Rb2/p130 Gene Transcription: A Novel Mechanism and a New Paradigm for Understanding the Biology of Lung Cancer. Mol Cancer Res. 9(2): 225-33 (2011). UNIVERSITY OF SASSARI UNIVERSITY OF SASSARI 10 Alessio N., Squillaro T., Cipollato M., Bagella L., Giordano A. and Galderisi U. The BRG1 ATPase of chromatin remodelling complexes is involved in modulation of mesenchymal stem cell senescence through RB-P53 pathways. Oncogene 29(40): 5452-63 (2010). 11 Tonini T., D'Andrilli G., Fucito A., Gaspa L., Bagella L. Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J Cell Physiol. 214(2): 295-300 (2008). 12 Bagella L., Sun A., Tonini T., Abbadessa G., Cottone G., Paggi M. G., De Luca A., Claudio P.P., Giordano A. A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity and cell cycle arrest. Oncogene 26(13): 1829-39 (2007). 13 Giordano A., Rossi A., Romano G., Bagella L. Tumor suppressor pRb2/p130 gene and its derived product Spa310 spacer domain as perspective candidates for cancer therapy. J Cell Physiol. 213(2): 403-6 (2007). 14 Tonini T., Bagella L., D’Andrilli G., Claudio P.P., Giordano A. EZH2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. Oncogene 23(28): 4930-7 (2004). 15 D’Andrilli G., Masciullo V., Bagella L., Tonini T., Minimo C., Zannoni G.F., Giuntoli II R.L., Carlson Jr. J.A., Soprano R.D., Soprano K.J., Scambia G., Giordano A. Frequent loss of pRb2/p130 in human ovarian carcinoma. Clin Cancer Res. 10(9): 3098-103 (2004). 16 Sano M., Abdellatif M., Oh H., Xie M., Bagella L., Giordano A., Michael L.H., DeMayo F.J., Schneider M.D. Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nature Medicine 11: 1310-7 (2002). 17 Simone C.*, Bagella L.*, Bellan